mecamylamine has been researched along with Nicotine Addiction in 74 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pre-treatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting." | 9.12 | Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. ( Creeden, CL; George, TP; Jatlow, PI; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2007) |
| "The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial." | 9.08 | Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. ( Behm, FM; Rose, JE; Westman, EC, 1998) |
| " In this study, we aim at deciphering the effects and possible mechanisms of prenatal severe hypoxia (PSH) on predisposition to nicotine addiction in adult rats." | 8.12 | Prenatal Hypoxia Affects Nicotine Consumption and Withdrawal in Adult Rats via Impairment of the Glutamate System in the Brain. ( Stratilov, VA; Tyulkova, EI; Vetrovoy, OV, 2022) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 7.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Individuals with schizophrenia have higher plasma nicotine levels in comparison to non-psychiatric smokers, even when differences in smoking are equated." | 6.74 | Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. ( Coppola, S; George, TP; Harrison, EL; McKee, SA; Weinberger, AH, 2009) |
| " We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pre-treatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting." | 5.12 | Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. ( Creeden, CL; George, TP; Jatlow, PI; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2007) |
| "The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial." | 5.08 | Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. ( Behm, FM; Rose, JE; Westman, EC, 1998) |
| " Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies." | 4.90 | Emerging drugs for the treatment of tobacco dependence: 2014 update. ( Ebbert, JO; Elrashidi, MY, 2014) |
| " Bupropion sustained release (SR) is the first non-nicotine pharmacological treatment approved for smoking cessation and is thought to be effective because of its dopaminergic activity on the pleasure and reward pathways in the mesolimbic system and nucleus accumbens." | 4.80 | New medications for nicotine dependence treatment. ( Hurt, RD, 1999) |
| " In this study, we aim at deciphering the effects and possible mechanisms of prenatal severe hypoxia (PSH) on predisposition to nicotine addiction in adult rats." | 4.12 | Prenatal Hypoxia Affects Nicotine Consumption and Withdrawal in Adult Rats via Impairment of the Glutamate System in the Brain. ( Stratilov, VA; Tyulkova, EI; Vetrovoy, OV, 2022) |
| " All mice were then, 96 hr later, challenged with mecamylamine (3 mg/kg), and tested for anxiety-like behaviors 30 min later." | 3.96 | The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal. ( Ahmad, SM; Hamid, A; Lutfy, K; Marquez, P; Nega, S, 2020) |
| " The nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine induced a larger increase in reward thresholds (ie, anhedonia) in the LgA rats than the ShA rats." | 3.96 | Relationship Between Nicotine Intake and Reward Function in Rats With Intermittent Short Versus Long Access to Nicotine. ( Bruijnzeel, AW; Esser, KA; Febo, M; Geste, JR; Levin, B; O'Dell, L; Pompilus, M; Wilks, I; Zhang, X, 2020) |
| "Cigarette smokers with brain damage involving the insular cortex display cessation of tobacco smoking, suggesting that this region may contribute to nicotine addiction." | 3.91 | N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. ( D'Aniello, E; Damaj, MI; Di Marzo, V; Donvito, G; Giordano, C; Guida, F; Ignatowska-Jankowska, BM; Jackson, A; Lichtman, AH; Maione, S; Mechoulam, R; Muldoon, P; Mustafa, MA; Parker, L; Petrie, GN; Piscitelli, F; Sim-Selley, L; Smoum, R; Vitale, RM, 2019) |
| " We analysed the time course of the global withdrawal score, the anxiety-like effects, monoamine concentrations, the brain-derived neurotrophic factor (BDNF) expression, the corticosterone plasmatic levels and [(3)H]epibatidine binding sites during NIC withdrawal precipitated by mecamylamine, a nicotinic receptor antagonist (MEC)." | 3.81 | Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal. ( Antonelli, MC; Balerio, GN; Bettler, B; Machado, LM; Pedrón, VT; Varani, AP, 2015) |
| " Chronic intermittent non-contingent, second-hand exposure to cigarette smoke or e-cig vapour led to similar brain cotinine and nicotine levels, similar urine cotinine levels and the similar up-regulation of α4β2 nicotinic acetylcholine receptors in different brain areas, but had different effects on body weight, food intake, and the signs of mecamylamine-precipitated and spontaneous withdrawal episodic memory and emotional responses." | 3.81 | Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice. ( Braida, D; Cannazza, G; Castellana, CN; Clementi, F; Fasoli, F; Gallesi, G; Gotti, C; Lucini, V; Moretti, M; Mucchietto, V; Ponzoni, L; Sala, M; Zoli, M, 2015) |
| "Humans escalate their cigarette smoking over time, and a major obstacle in the field of pre-clinical nicotine addiction research has been the inability to produce escalated nicotine self-administration in rats." | 3.80 | Nicotine vapor inhalation escalates nicotine self-administration. ( Abdel, AY; Baynes, B; George, O; Gilpin, NW; Weil, MT; Whitaker, AM, 2014) |
| "Thus, it is suggested that src kinase is involved in the development of nicotine dependence-induced precipitation of its withdrawal syndrome and thus may serve as a viable pharmacological target to tackle the problem of nicotine addiction." | 3.78 | SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice. ( Arora, S; Rehni, AK; Singh, TG, 2012) |
| "Nicotine addiction is a chronic disorder characterized by a relatively high rate of relapse even after long period of abstinence." | 3.76 | Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. ( Biala, G; Budzynska, B; Staniak, N, 2010) |
| " Although adolescents may exhibit a greater susceptibility to nicotine addiction, relatively little is known about the influence of the aversive effects of nicotine withdrawal in maintaining smoking behavior." | 3.74 | Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. ( Lê, AD; Li, Z; Shram, MJ; Siu, EC; Tyndale, RF, 2008) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 3.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving." | 3.73 | Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. ( Dudas, MM; George, TP; Jatlow, PI; Krishnan-Sarin, S; Sacco, KA; Seyal, A; Termine, A; Vessicchio, JC; Wexler, BE, 2005) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| " Because nucleus accumbens nicotinic receptors are important in nicotine addiction and because nicotinic activity can interact with opioid action, we investigated the contribution of nucleus accumbens nicotinic receptors to opioid-mediated analgesia/antinociception." | 3.71 | Nicotine withdrawal hyperalgesia and opioid-mediated analgesia depend on nicotine receptors in nucleus accumbens. ( Gear, RW; Levine, JD; Schmidt, BL; Tambeli, CH, 2001) |
| "Individuals with schizophrenia have higher plasma nicotine levels in comparison to non-psychiatric smokers, even when differences in smoking are equated." | 2.74 | Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. ( Coppola, S; George, TP; Harrison, EL; McKee, SA; Weinberger, AH, 2009) |
| "Mecamylamine pretreatment prevented the increase in alpha frequency caused by the 4 mg gum dose but not the 8 mg dose." | 2.66 | Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. ( Henningfield, JE; Herning, RI; Pickworth, WB, 1988) |
| "Cigarette smoking and resultant nicotine dependence remain major public health problems." | 1.51 | Differential expression of nicotine withdrawal as a function of developmental age in the rat. ( Hsu, LM; Keeley, RJ; Lu, H; Mayer, TE; Stein, EA; Yang, Y, 2019) |
| "The nicotine plasma levels were also measured with or without methoxsalen pretreatment." | 1.40 | Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. ( Bagdas, D; Damaj, MI; Muldoon, PP; Tyndale, RF; Zhu, AZ, 2014) |
| "Nicotine dependence was induced by implanting minipumps that delivered a nicotine solution." | 1.38 | Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. ( Alexander, JC; Bishnoi, M; Bruijnzeel, AW; Ford, J; Ji, Y; Rogers, JA; Scheick, S, 2012) |
| "Tobacco dependence is an addiction with high rates of relapse, resulting in multiple quit attempts in individuals who are trying to stop smoking." | 1.38 | Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. ( Blendy, JA; Hilario, MR; Turner, JR, 2012) |
| "Because nicotine dependence (ND) is highly comorbid with schizophrenia and other substance abuse, we examined the association of HINT1 with ND." | 1.37 | Association of the histidine-triad nucleotide-binding protein-1 (HINT1) gene variants with nicotine dependence. ( Aggen, SH; Chen, J; Chen, Q; Chen, X; Jackson, KJ; Kendler, KS, 2011) |
| "Tobacco smoke exposure leads to nicotine dependence as indicated by precipitated affective and somatic withdrawal signs and induces an upregulation of nAChRs in the hippocampus." | 1.36 | Tobacco smoke exposure induces nicotine dependence in rats. ( Bruijnzeel, AW; Davenport, JJ; Derendorf, H; Geier, JE; Gold, MS; Pauly, JR; Sabarinath, SN; Shah, HP; Small, E; Yamada, H; Yavarovich, KR, 2010) |
| "Nicotine dependence was assessed by examining physical signs of withdrawal following an injection of the nicotinic antagonist mecamylamine (1." | 1.34 | 'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. ( Koob, GF; O'Dell, LE, 2007) |
| " For rats with access to VS (VS-Only), nicotine (NIC-Only), both reinforcers contingent upon one response (NIC+VS) or both reinforcers contingent upon separate responses (2-Lever), unit dose-response relationships (0, 30, 60, or 90 microg/kg/infusion, free base) were determined over a 22-day acquisition period." | 1.34 | The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine. ( Caggiula, AR; Donny, EC; Liu, X; Palmatier, MI; Sved, AF, 2007) |
| "Nicotine dependence was induced via osmotic minipump in adolescent rats (releasing 22." | 1.33 | Withdrawal from chronic nicotine in adolescent and adult rats. ( Spear, LP; Wilmouth, CE, 2006) |
| "Nicotine was then administered s." | 1.33 | Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats. ( Balster, RL; Beardsley, PM; Vann, RE, 2006) |
| "Adolescents did not display the decreases in brain reward function observed in adults experiencing withdrawal, and displayed fewer somatic signs of nicotine withdrawal relative to adults regardless of the dosing procedure used." | 1.33 | Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. ( Bruijnzeel, AW; Goldberger, BA; Koob, GF; Markou, A; Merves, ML; O'Dell, LE; Parsons, LH; Richardson, HN; Smith, RT, 2006) |
| "Nicotine dependence was induced by continuous nicotine infusion through osmotic minipumps." | 1.32 | Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration. ( Bespalov, A; Markou, A; Semenova, S, 2003) |
| "Nicotine withdrawal was significantly attenuated in knock-out mutants when compared with wild-type mice." | 1.31 | Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. ( Berrendero, F; Kieffer, BL; Maldonado, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.70) | 18.7374 |
| 1990's | 5 (6.76) | 18.2507 |
| 2000's | 35 (47.30) | 29.6817 |
| 2010's | 28 (37.84) | 24.3611 |
| 2020's | 4 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Rather, IIG | 1 |
| Behl, T | 1 |
| Sehgal, A | 1 |
| Singh, S | 1 |
| Sharma, N | 1 |
| Sharma, A | 1 |
| Bhatia, S | 1 |
| Al-Harrasi, A | 1 |
| Khan, N | 1 |
| Khan, H | 1 |
| Bungau, S | 1 |
| Stratilov, VA | 1 |
| Vetrovoy, OV | 1 |
| Tyulkova, EI | 1 |
| Keeley, RJ | 1 |
| Mayer, TE | 1 |
| Hsu, LM | 2 |
| Lu, H | 2 |
| Yang, Y | 2 |
| Stein, EA | 2 |
| Nega, S | 1 |
| Marquez, P | 1 |
| Hamid, A | 1 |
| Ahmad, SM | 1 |
| Lutfy, K | 1 |
| Pipkin, JA | 1 |
| Cruz, B | 1 |
| Flores, RJ | 2 |
| Hinojosa, CA | 1 |
| Carcoba, LM | 2 |
| Ibarra, M | 1 |
| Francis, W | 1 |
| Nazarian, A | 1 |
| O'Dell, LE | 6 |
| Yuan, M | 1 |
| Malagon, AM | 1 |
| Yasuda, D | 1 |
| Belluzzi, JD | 1 |
| Leslie, FM | 1 |
| Zaveri, NT | 1 |
| Natividad, LA | 1 |
| Donvito, G | 1 |
| Piscitelli, F | 1 |
| Muldoon, P | 1 |
| Jackson, A | 2 |
| Vitale, RM | 1 |
| D'Aniello, E | 1 |
| Giordano, C | 1 |
| Ignatowska-Jankowska, BM | 2 |
| Mustafa, MA | 1 |
| Guida, F | 1 |
| Petrie, GN | 1 |
| Parker, L | 1 |
| Smoum, R | 1 |
| Sim-Selley, L | 1 |
| Maione, S | 1 |
| Lichtman, AH | 2 |
| Damaj, MI | 5 |
| Di Marzo, V | 1 |
| Mechoulam, R | 1 |
| Javadi-Paydar, M | 1 |
| Kerr, TM | 1 |
| Harvey, EL | 1 |
| Cole, M | 1 |
| Taffe, MA | 1 |
| Geste, JR | 1 |
| Levin, B | 1 |
| Wilks, I | 1 |
| Pompilus, M | 1 |
| Zhang, X | 1 |
| Esser, KA | 1 |
| Febo, M | 2 |
| O'Dell, L | 1 |
| Bruijnzeel, AW | 6 |
| Varani, AP | 2 |
| Antonelli, MC | 2 |
| Balerio, GN | 2 |
| Muldoon, PP | 2 |
| Dash, B | 1 |
| Lukas, RJ | 1 |
| Li, MD | 1 |
| Elrashidi, MY | 1 |
| Ebbert, JO | 1 |
| Bagdas, D | 1 |
| Zhu, AZ | 1 |
| Tyndale, RF | 2 |
| Pedrón, VT | 1 |
| Machado, LM | 1 |
| Bettler, B | 1 |
| Ponzoni, L | 1 |
| Moretti, M | 1 |
| Sala, M | 1 |
| Fasoli, F | 1 |
| Mucchietto, V | 1 |
| Lucini, V | 1 |
| Cannazza, G | 1 |
| Gallesi, G | 1 |
| Castellana, CN | 1 |
| Clementi, F | 1 |
| Zoli, M | 1 |
| Gotti, C | 1 |
| Braida, D | 1 |
| Bowers, MS | 1 |
| Maldoon, PP | 1 |
| Brynildsen, JK | 1 |
| Najar, J | 1 |
| Vaupel, DB | 1 |
| Ross, TJ | 1 |
| de Moura, FB | 1 |
| McMahon, LR | 1 |
| Qi, X | 1 |
| Guzhva, L | 1 |
| Yang, Z | 1 |
| Shan, Z | 1 |
| Wang, KKW | 1 |
| Rose, JE | 4 |
| Trigo, JM | 1 |
| Zimmer, A | 2 |
| Maldonado, R | 4 |
| Roiko, SA | 1 |
| Harris, AC | 2 |
| LeSage, MG | 1 |
| Keyler, DE | 1 |
| Pentel, PR | 1 |
| Engelmann, JM | 1 |
| Radke, AK | 1 |
| Gewirtz, JC | 1 |
| McKee, SA | 1 |
| Weinberger, AH | 2 |
| Harrison, EL | 1 |
| Coppola, S | 1 |
| George, TP | 3 |
| Small, E | 1 |
| Shah, HP | 1 |
| Davenport, JJ | 1 |
| Geier, JE | 1 |
| Yavarovich, KR | 1 |
| Yamada, H | 1 |
| Sabarinath, SN | 1 |
| Derendorf, H | 1 |
| Pauly, JR | 1 |
| Gold, MS | 1 |
| Chatterjee, S | 1 |
| Bartlett, SE | 1 |
| Biala, G | 2 |
| Staniak, N | 1 |
| Budzynska, B | 1 |
| Jackson, KJ | 1 |
| Chen, Q | 1 |
| Chen, J | 1 |
| Aggen, SH | 1 |
| Kendler, KS | 1 |
| Chen, X | 1 |
| Scott, D | 1 |
| Hiroi, N | 1 |
| Plaza-Zabala, A | 1 |
| Flores, Á | 1 |
| Berrendero, F | 3 |
| Rehni, AK | 1 |
| Singh, TG | 1 |
| Arora, S | 1 |
| Ford, J | 1 |
| Rogers, JA | 1 |
| Scheick, S | 1 |
| Ji, Y | 1 |
| Bishnoi, M | 1 |
| Alexander, JC | 1 |
| Hilario, MR | 1 |
| Turner, JR | 1 |
| Blendy, JA | 1 |
| Manbeck, KE | 1 |
| Schmidt, CE | 1 |
| Shelley, D | 1 |
| Gilpin, NW | 1 |
| Whitaker, AM | 1 |
| Baynes, B | 1 |
| Abdel, AY | 1 |
| Weil, MT | 1 |
| George, O | 1 |
| Kieffer, BL | 1 |
| Semenova, S | 1 |
| Bespalov, A | 1 |
| Markou, A | 6 |
| Kao, W | 1 |
| Martin, BR | 1 |
| Paterson, NE | 2 |
| Behm, FM | 3 |
| Ghozland, S | 1 |
| Koob, GF | 4 |
| Sahraei, H | 1 |
| Falahi, M | 1 |
| Zarrindast, MR | 1 |
| Sabetkasaei, M | 1 |
| Ghoshooni, H | 1 |
| Khalili, M | 1 |
| Mendizábal, V | 1 |
| Robledo, P | 1 |
| Galeote, L | 1 |
| Bilkei-Gorzo, A | 1 |
| Weglinska, B | 1 |
| Sacco, KA | 2 |
| Termine, A | 1 |
| Seyal, A | 1 |
| Dudas, MM | 1 |
| Vessicchio, JC | 2 |
| Krishnan-Sarin, S | 1 |
| Jatlow, PI | 2 |
| Wexler, BE | 1 |
| Vann, RE | 2 |
| Balster, RL | 2 |
| Beardsley, PM | 1 |
| Liu, X | 2 |
| Caggiula, AR | 2 |
| Yee, SK | 1 |
| Nobuta, H | 1 |
| Poland, RE | 1 |
| Pechnick, RN | 1 |
| Smith, RT | 2 |
| Parsons, LH | 1 |
| Merves, ML | 1 |
| Goldberger, BA | 1 |
| Richardson, HN | 1 |
| Rosecrans, JA | 1 |
| James, JR | 1 |
| Philibin, SD | 1 |
| Robinson, SE | 1 |
| Chen, SA | 1 |
| Specio, SE | 1 |
| Zorrilla, EP | 1 |
| Palmatier, MI | 1 |
| Donny, EC | 1 |
| Sved, AF | 1 |
| Middleton, LS | 1 |
| Crooks, PA | 1 |
| Wedlund, PJ | 1 |
| Cass, WA | 1 |
| Dwoskin, LP | 1 |
| Wilmouth, CE | 1 |
| Spear, LP | 1 |
| Phillips, JM | 1 |
| Ehrlichman, RS | 1 |
| Siegel, SJ | 1 |
| Creeden, CL | 1 |
| Wing, VC | 1 |
| Shoaib, M | 1 |
| Shram, MJ | 1 |
| Siu, EC | 1 |
| Li, Z | 1 |
| Lê, AD | 1 |
| Johnson, PM | 1 |
| Hollander, JA | 1 |
| Kenny, PJ | 1 |
| Henningfield, JE | 2 |
| Bobrie, G | 1 |
| Battaglia, C | 1 |
| Loufrani, E | 1 |
| Ménard, J | 1 |
| Westman, EC | 1 |
| Malin, DH | 1 |
| Lake, JR | 1 |
| Shenoi, M | 1 |
| Upchurch, TP | 1 |
| Johnson, SC | 1 |
| Schweinle, WE | 1 |
| Cadle, CD | 1 |
| Hildebrand, BE | 2 |
| Panagis, G | 2 |
| Svensson, TH | 2 |
| Nomikos, GG | 2 |
| Matsuyama, S | 1 |
| Matsumoto, A | 1 |
| Enomoto, T | 1 |
| Nishizaki, T | 1 |
| Marx, CE | 1 |
| McIntosh, E | 1 |
| Wilson, WH | 1 |
| McEvoy, JP | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Schmidt, BL | 1 |
| Tambeli, CH | 1 |
| Gear, RW | 1 |
| Levine, JD | 1 |
| Ramsey, C | 1 |
| Ritchie, JC | 1 |
| Hurt, RD | 1 |
| Pickworth, WB | 1 |
| Herning, RI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| Effectiveness of Preloaded Combination Nicotine Replacement Therapy on Smoking Cessation of Adult Population in Kazakhstan- A Randomized Controlled Trial[NCT05484505] | Early Phase 1 | 200 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for mecamylamine and Nicotine Addiction
| Article | Year |
|---|---|
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mec | 2014 |
New findings on nicotine addiction and treatment.
Topics: Animals; Benzazepines; Bupropion; Humans; Mecamylamine; Motivation; Nicotine; Nicotinic Antagonists; | 2009 |
Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Benzazepines; Brain; Humans; Mecamyl | 2010 |
Pharmacologic basis and treatment of cigarette smoking.
Topics: Animals; Chewing Gum; Compulsive Behavior; Conditioning, Operant; Drug Interactions; Humans; Mecamyl | 1984 |
[Drug aid to tobacco withdrawal].
Topics: Humans; Mecamylamine; Nicotine; Smoking Cessation; Tobacco Use Disorder | 1993 |
New medications for nicotine dependence treatment.
Topics: Administration, Cutaneous; Administration, Inhalation; Bupropion; Chewing Gum; Delayed-Action Prepar | 1999 |
6 trials available for mecamylamine and Nicotine Addiction
| Article | Year |
|---|---|
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study.
Topics: Adolescent; Adult; Behavior, Addictive; Double-Blind Method; Female; Humans; Male; Mecamylamine; Mid | 2009 |
Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.
Topics: Administration, Cutaneous; Adult; Behavior Therapy; Extinction, Psychological; Female; Ganglionic St | 2004 |
Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.
Topics: Acute Disease; Adult; Cotinine; Demography; Depression; Female; Humans; Male; Mecamylamine; Nicotine | 2007 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
Topics: Adult; Affect; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Mecamylamine; Nico | 1998 |
Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms.
Topics: Administration, Cutaneous; Adult; Female; Humans; Male; Mecamylamine; Monoamine Oxidase; Neostigmine | 2001 |
Mecamylamine reduces some EEG effects of nicotine chewing gum in humans.
Topics: Adult; Chewing Gum; Electroencephalography; Humans; Male; Mecamylamine; Middle Aged; Nicotine; Tobac | 1988 |
62 other studies available for mecamylamine and Nicotine Addiction
| Article | Year |
|---|---|
Exploration of potential role of Rho GTPase in nicotine dependence-induced withdrawal syndrome in mice.
Topics: Animals; Mecamylamine; Mice; Nicotine; rho GTP-Binding Proteins; Substance Withdrawal Syndrome; Toba | 2022 |
Prenatal Hypoxia Affects Nicotine Consumption and Withdrawal in Adult Rats via Impairment of the Glutamate System in the Brain.
Topics: Animals; Dopamine; Glutamic Acid; Hypoxia; Mecamylamine; Nicotine; Nicotinic Antagonists; Nucleus Ac | 2022 |
Differential expression of nicotine withdrawal as a function of developmental age in the rat.
Topics: Age Factors; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Infusions, Subcutaneous; L | 2019 |
The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal.
Topics: Animals; Anxiety; Conditioning, Psychological; Depression; Female; Male; Mecamylamine; Mice; Mice, I | 2020 |
Both nicotine reward and withdrawal are enhanced in a rodent model of diabetes.
Topics: Animals; Conditioning, Psychological; Diabetes Mellitus, Experimental; Dose-Response Relationship, D | 2017 |
The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Cholinergic Agonists; Conditioning, Operant; Disea | 2017 |
Amino acid modulation of dopamine in the nucleus accumbens mediates sex differences in nicotine withdrawal.
Topics: Amino Acids; Animals; Disease Models, Animal; Dopamine; Female; Glutamic Acid; Male; Mecamylamine; N | 2018 |
N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice.
Topics: Animals; Brain Injuries, Traumatic; Cerebral Cortex; Conditioning, Classical; Glycine; Male; Mecamyl | 2019 |
Effects of nicotine and THC vapor inhalation administered by an electronic nicotine delivery system (ENDS) in male rats.
Topics: Administration, Inhalation; Animals; Body Temperature; Central Nervous System Stimulants; Dronabinol | 2019 |
Relationship Between Nicotine Intake and Reward Function in Rats With Intermittent Short Versus Long Access to Nicotine.
Topics: Anhedonia; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrodes, Impl | 2020 |
Mecamylamine-precipitated nicotine withdrawal syndrome and its prevention with baclofen: an autoradiographic study of α4β2 nicotinic acetylcholine receptors in mice.
Topics: Analysis of Variance; Animals; Autoradiography; Baclofen; Brain; Cholinergic Agents; Disease Models, | 2013 |
The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice.
Topics: Animals; Anisoles; Behavior, Animal; Cocaine; Conditioning, Psychological; Cyclohexanols; Dose-Respo | 2013 |
A signal peptide missense mutation associated with nicotine dependence alters α2*-nicotinic acetylcholine receptor function.
Topics: Acetylcholine; Amino Acid Sequence; Animals; Genetic Predisposition to Disease; Humans; Mecamylamine | 2014 |
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.
Topics: Animals; Anxiety; Aryl Hydrocarbon Hydroxylases; Conditioning, Psychological; Cytochrome P450 Family | 2014 |
Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal.
Topics: Animals; Anxiety; Brain; Brain-Derived Neurotrophic Factor; Corticosterone; Disease Models, Animal; | 2015 |
Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice.
Topics: Animals; Body Weight; Brain; Cotinine; Disease Models, Animal; Eating; Electronic Nicotine Delivery | 2015 |
N-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice.
Topics: Acetylcysteine; Animals; Association Learning; Dose-Response Relationship, Drug; Male; Mecamylamine; | 2016 |
A novel method to induce nicotine dependence by intermittent drug delivery using osmotic minipumps.
Topics: Drug Delivery Systems; Mecamylamine; Osmosis; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2016 |
Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.
Topics: Animals; Cocaine; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2016 |
Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.
Topics: Animals; Anxiety; Corticotropin-Releasing Hormone; Dependovirus; Disease Models, Animal; Genetic Vec | 2016 |
Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.
Topics: Animals; Anxiety; beta-Endorphin; Conditioning, Classical; Crosses, Genetic; Exploratory Behavior; F | 2009 |
Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats.
Topics: Animals; Antibodies, Monoclonal; Brain; Dose-Response Relationship, Drug; Immunization, Passive; Imm | 2009 |
Potentiated startle as a measure of the negative affective consequences of repeated exposure to nicotine in rats.
Topics: Acoustic Stimulation; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Clonidine; Dose-R | 2009 |
Tobacco smoke exposure induces nicotine dependence in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Autoradiography; Dentate Gyrus; Dose-Response Rela | 2010 |
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
Topics: Animals; Benzazepines; Conditioning, Classical; Dose-Response Relationship, Drug; Male; Mecamylamine | 2010 |
Association of the histidine-triad nucleotide-binding protein-1 (HINT1) gene variants with nicotine dependence.
Topics: Adolescent; Adult; Aged; Animals; Autopsy; Brain; Gene Frequency; Genetic Predisposition to Disease; | 2011 |
Emergence of dormant conditioned incentive approach by conditioned withdrawal in nicotine addiction.
Topics: Animals; Behavior, Addictive; Choice Behavior; Conditioning, Psychological; Cues; Male; Mecamylamine | 2010 |
Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal.
Topics: Animals; Antigens, Surface; Benzoxazoles; Intracellular Signaling Peptides and Proteins; Isoquinolin | 2012 |
SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Indoles; Injections, Intr | 2012 |
Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Amygdala; Animals; | 2012 |
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice.
Topics: Analysis of Variance; Animals; Brain; Conditioning, Operant; Electric Stimulation; Mecamylamine; Mic | 2012 |
Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine.
Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; M | 2013 |
Nicotine vapor inhalation escalates nicotine self-administration.
Topics: Analysis of Variance; Animals; Behavior, Animal; Conditioning, Operant; Disease Models, Animal; Dose | 2014 |
Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice.
Topics: Analgesics; Animals; Behavior, Animal; Conditioning, Psychological; Locomotion; Mecamylamine; Mice; | 2002 |
Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration.
Topics: Animals; Behavior, Animal; Injections, Intravenous; Male; Mecamylamine; Mice; Mice, Inbred DBA; Nico | 2003 |
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse.
Topics: Animals; Disease Models, Animal; Male; Mecamylamine; Mice; Mice, Inbred ICR; Nicotine; Nicotinic Ant | 2003 |
Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cocaine; Dopamine Uptake Inhibitors; Dose-Response | 2004 |
Nicotine withdrawal in adolescent and adult rats.
Topics: Adolescent; Age Factors; Analysis of Variance; Animals; Blinking; Disease Models, Animal; Drug Admin | 2004 |
The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice.
Topics: Animals; Arginine; Conditioning, Operant; Dose-Response Relationship, Drug; Enzyme Inhibitors; Male; | 2004 |
Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene.
Topics: Analgesics; Animals; Conditioning, Classical; Dopamine; Enkephalins; Female; Hot Temperature; Male; | 2005 |
Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Maze Learning; Mecamylamine; Mice; Motor | 2005 |
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.
Topics: Adult; Attention; Behavior, Addictive; Cognition; Cognition Disorders; Comorbidity; Female; Humans; | 2005 |
Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats.
Topics: Animals; Association Learning; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, | 2006 |
Reinstatement of nicotine-seeking behavior by drug-associated stimuli after extinction in rats.
Topics: Animals; Association Learning; Cues; Disease Models, Animal; Extinction, Psychological; Male; Mecamy | 2006 |
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction.
Topics: Age Factors; Animals; Behavior, Animal; Cotinine; Dose-Response Relationship, Drug; Male; Mecamylami | 2006 |
Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.
Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Bupropion; Dopamine; Dopamine Uptake Inhibitors; | 2006 |
Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats.
Topics: Animals; Circadian Rhythm; Eating; Extinction, Psychological; Male; Mecamylamine; Nicotine; Rats; Ra | 2007 |
The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine.
Topics: Acetylcholine; Animals; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Extinction, Psycho | 2007 |
Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose | 2007 |
Withdrawal from chronic nicotine in adolescent and adult rats.
Topics: Age Factors; Animals; Anxiety; Body Weight; Male; Maze Learning; Mecamylamine; Rats; Rats, Sprague-D | 2006 |
Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.
Topics: Acetylcholine; Action Potentials; Animals; Biological Clocks; Brain; Cognition Disorders; Evoked Pot | 2007 |
'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration.
Topics: Animals; Conditioning, Operant; Food; Infusions, Intravenous; Male; Mecamylamine; Nicotine; Nicotini | 2007 |
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Dose-Response Relationship, Drug; | 2007 |
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
Topics: Aging; Animals; Avoidance Learning; Conditioning, Operant; Dose-Response Relationship, Drug; Injecti | 2008 |
Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies.
Topics: Animals; Brain; Drug Implants; Electrodes, Implanted; Male; Mecamylamine; Mice; Mice, Inbred C57BL; | 2008 |
The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat.
Topics: Animals; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Nitric Oxide Synth | 1998 |
Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Hydroxyindoleacetic Acid; Male; Mecamylamine; Mot | 1999 |
Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome.
Topics: Amygdala; Animals; Behavior, Animal; Biological Transport; Brain Chemistry; Dopamine; Male; Mecamyla | 2000 |
Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Choline; Dentate Gyrus; Long-Term P | 2000 |
Mecamylamine increases cigarette smoking in psychiatric patients.
Topics: Adult; Analysis of Variance; Central Nervous System Stimulants; Double-Blind Method; Female; Humans; | 2000 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |
Nicotine withdrawal hyperalgesia and opioid-mediated analgesia depend on nicotine receptors in nucleus accumbens.
Topics: Analgesia; Animals; Capsaicin; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; | 2001 |